生物股份公告，公司于2025年10月27日召开第十二届董事会第四次会议，审议通过了《关于拟回购注销 2023年员工持股计划部分股票的议案》。因5名离职持有人尚未解锁的权益份额，公司将回购注销12万 股股票，回购价格为6.23元/股。此次回购注销完成后，公司股本结构将有所变动，但不会对公司的经 营业绩、财务状况产生实质性重大影响。 ...

生物股份公告，第三季度营收为4.23亿元，同比增长17.76%；净利润为1.01亿元，同比增长116.40%。 前三季度营收为10.42亿元，同比增长7.38%；净利润为1.61亿元，同比下降4.85%。 ...

Group 1 - The Agricultural, Animal Husbandry, and Fishery ETF (159275) showed stable performance with a 1.0% increase in intraday price and a transaction volume of 5.0954 million yuan, bringing the fund's latest scale to 209 million yuan [1] - Among the constituent stocks, Zhongxing Junye reached the daily limit, while Xiaoming Co. and Shengnong Development saw significant gains of 4.34% and 3.99% respectively. Conversely, Chenguang Biotech experienced a notable decline of 3.19%, with Honghui Fruits and Vegetables and Shennong Seed Industry also showing weaker performance with drops of 1.04% and 0.88% respectively [1] - The Ministry of Agriculture and Rural Affairs held a meeting on October 21 to discuss increasing grain and oil crop yields, emphasizing the promotion of technology integration and high-performance agricultural machinery, particularly supporting the promotion of genetically modified technology to enhance grain yields, which may benefit related seed and planting companies [1] - The core breeding source rate for lean pork in China has surpassed 90%, indicating progress in self-sufficiency in the livestock breeding industry, with leading companies like Muyuan Foods continuing to drive innovation in breeding [1] - According to Citic Securities, the supply in the pig farming industry continues to increase, with rising demand for fat pigs driving up prices, although farming remains unprofitable, potentially accelerating capacity reduction [1] - In the poultry farming sector, frequent outbreaks of avian influenza overseas create uncertainty in the introduction of grandparent stock chickens, which is favorable for the white feather chicken industry chain prices [1] - The seed industry is focusing on the progress of biological breeding expansion, the promotion of genetically modified corn, and industry mergers and acquisitions [1] - The demand in the animal health industry is expected to bottom out, with new product launches providing growth momentum. The domestic pet market continues to grow rapidly, while exports are only slightly affected by tariff disruptions [1] Group 2 - The Agricultural, Animal Husbandry, and Fishery ETF (159275) and its linked funds (Link A: 013471, Link C: 013472) passively track the Agricultural, Animal Husbandry, and Fishery Index, with the top ten weighted stocks including Muyuan Foods, Wens Foodstuff Group, Haida Group, New Hope, Meihua Biological, Dabeinong, Shengnong Development, Biological Co., Beidahuang, and Longping High-Tech [2]

Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2]. Financial Data - The third-quarter financial report has not been audited [8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - The company has provided details regarding the total number of shareholders and the shareholding status of the top ten shareholders [4][5]. Strategic Cooperation - Jiangsu Chenwei Ecological Park Technology Co., Ltd. has signed a strategic cooperation agreement with Jiangyin Xinguangfa Trading Co., Ltd. to provide a stable supply of seedlings, with a total contract value of 26,098,107 yuan [5]. Governance and Compliance - The company is in the process of formulating and revising several governance systems to enhance operational standards, in accordance with relevant laws and regulations [9][11]. - The board of directors has approved the third-quarter report and various governance proposals, all receiving unanimous support [12][14].

Core Viewpoint - The announcement details the self-inspection report regarding the trading activities of insiders and incentive participants related to the 2025 A-share restricted stock incentive plan, confirming compliance with relevant regulations and the absence of insider trading activities [1][6][7]. Group 1: Incentive Plan Overview - The company convened meetings on September 26, 2025, to approve the draft of the 2025 A-share restricted stock incentive plan and related proposals [1]. - The incentive plan was disclosed on September 27, 2025, in accordance with the relevant laws and regulations [1][2]. Group 2: Self-Inspection Process - The self-inspection covered the trading activities of insiders and incentive participants from March 27, 2025, to September 26, 2025 [2]. - All insiders filled out the "Insider Information Registration Form," and the company confirmed trading activities with the China Securities Depository and Clearing Corporation [3]. Group 3: Trading Activities Findings - During the self-inspection period, five individuals were found to have traded company stocks, but these trades occurred before they were aware of the insider information related to the incentive plan [4]. - Other than the five individuals, no other insiders engaged in stock trading during the self-inspection period [5]. Group 4: Compliance and Conclusion - The company adhered to the information disclosure management regulations and internal confidentiality measures throughout the planning of the incentive plan [6]. - No evidence of insider trading or information leakage was found prior to the public disclosure of the incentive plan [7].

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]

Group 1 - The company has decided to cancel the repurchased A-shares and reduce its registered capital due to not utilizing all repurchased shares for employee stock ownership plans or equity incentives within the stipulated three-year period [2][4] - The total number of shares will decrease from 247,449,899 to 247,043,801, with A-shares reducing from 114,778,999 to 114,372,901 [2] - The registered capital will be reduced from RMB 247,449,899 to RMB 247,043,801 following the cancellation of 406,098 shares [2] Group 2 - The company held its first extraordinary general meeting of shareholders on October 23, 2025, where the resolution for the cancellation of repurchased shares was approved [10][14] - The meeting was conducted in compliance with the relevant laws and regulations, with all directors present [10][15] - All resolutions, including the one regarding the cancellation of repurchased shares, were passed with more than two-thirds of the voting rights held by attending shareholders [14]

证券之星消息，10月23日动物保健板块较上一交易日下跌0.88%，生物股份领跌。当日上证指数报收于 3922.41，上涨0.22%。深证成指报收于13025.45，上涨0.22%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002141 | 后丰控股 | 4.03 | 2.03% | 32.37万 | 1.29亿 | | 002868 | *ST绿康 | 28.90 | 1.44% | 1.07万 | 3075.79万 | | 603566 | 普莱柯 | 14.11 | 0.71% | 2.80万 | 3923.90万 | | 600195 | 中牧股份 | 7.44 | 0.40% | 6.17万 | 4556.91万 | | 603718 | 海利生物 | 7.05 | 0.14% | 5.07万 | 3564.93万 | | 002688 | 金河生物 | 6.68 | 0.00% | 10.42万 | 6913.79万 | | 920275 | 驱动力 ...

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - The announcement details a strategic cooperation agreement between Liaoning Chengda Biological Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences, focusing on the prevention of vector-borne infectious diseases and collaborative research projects [2][15]. Group 1: Agreement Overview - The strategic cooperation agreement is an intention-based collaboration aimed at addressing emerging infectious diseases, particularly vector-borne diseases [2][10]. - The agreement was signed on October 21, 2025, in Shenyang, Liaoning Province [5]. - The agreement does not require board or shareholder approval, as it is an intention-based agreement [7][8]. Group 2: Parties Involved - The Institute of Microbiology is a research institution with a registered capital of 63.23 million yuan, located in Beijing [4]. - There is no related party relationship between the Institute of Microbiology and Chengda Biological [4]. Group 3: Cooperation Details - The cooperation will focus on joint research projects, strategic consulting for disease prevention, and deep integration of industry and academia [10][11]. - A joint laboratory will be established to support the development of a key laboratory for synthetic immunology and vaccine manufacturing [11]. - Both parties will share knowledge and conduct training to enhance technological capabilities in the field of infectious disease prevention [11]. Group 4: Impact on Company - The collaboration is expected to integrate top resources from the Institute of Microbiology with the company's vaccine development platform, accelerating the research and development of vaccines and biopharmaceuticals [15]. - The partnership aligns with the company's long-term strategy to focus on vaccines and expand into the biopharmaceutical sector, laying a solid foundation for building a biopharmaceutical industry cluster [15]. - The agreement is not expected to have a direct impact on the company's performance in 2025, with specific effects dependent on future project developments [2][15].